1-2 of 2
Amy D. Rock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

Mark P. Rubinstein, Cameron Williams, Caroline Mart, Jonathan Beall, Linda MacPherson, Joseph Azar, Marzena Swiderska-Syn, Paolo Manca, Barry C. Gibney, Mark D. Robinson, Carsten Krieg, Elizabeth G. Hill, Sharif A. Taha, Amy D. Rock, John H. Lee, Patrick Soon-Shiong, John Wrangle
Journal: The Journal of Immunology
J Immunol (2022) 208 (6): 1362–1370.
https://doi.org/10.4049/jimmunol.2100066
Published: 15 March 2022
View article titled, Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
Open the PDF for Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers in another window
Add to Citation Manager
Includes: Supplementary data
Journal Articles

The IL-15 receptor agonist N-803 combined with the anti-CD20 monoclonal antibody rituximab expands NK and CD8 T cells and alters single cell immune transcriptomes in a phase 1 clinical trial in lymphoma

Jennifer Ann Foltz-Stringfellow, Nancy L. Bartlett, Ethan McClain, Michelle Becker-Hapak, Brian T. Hess, Veronika Bachanova, Melissa M. Berrien-Elliott, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F. Cashen, Kristin McDaniels, Chaz Moreno, Feng Gao, Obi Griffith, Malachi Griffith, Julia A. Wagner, Amy D. Rock, Patrick Soon-Shiong, John Lee, Allegra A. Petti, Todd A Fehniger
Journal: The Journal of Immunology
J Immunol (2020) 204 (1_Supplement): 246.7.
https://doi.org/10.4049/jimmunol.204.Supp.246.7
Published: 01 May 2020
View article titled, The IL-15 receptor agonist N-803 combined with the anti-CD20 monoclonal antibody rituximab expands NK and CD8 T cells and alters single cell immune transcriptomes in a phase 1 clinical trial in lymphoma
Add to Citation Manager